Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients with ESR1-mutated, ER-positive, HER2-negative ABC By Ogkologos - June 4, 2025 471 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the VERITAC-2 study Source RELATED ARTICLESMORE FROM AUTHOR A Short-Course Dose Escalation Strategy Could Improve Ability to Reach Target Dose of Adjuvant Abemaciclib in High-Risk Early-Stage HR-positive, HER2-negative Breast Cancer FDA Approves Ziftomenib for Relapsed or Refractory Acute Myeloid Leukaemia with a NPM1 Mutation NEPA Plus Dexamethasone Provide Superior Chemotherapy-Induced Nausea and Vomiting Prevention Compared with SoC Antiemetic Prophylaxis MOST POPULAR Smoking Initiation Shifting from Teens to Young Adults November 6, 2020 Sacituzumab Govitecan Does Not Demonstrate a Statistically Significant OS Improvement in... July 30, 2024 ‘Normal’ cells and ‘cancer’s surprising circular DNA’: Inside Cancer Grand Challenges... June 23, 2022 Encouraging Single-Agent Antitumour Activity of Divarasib Across KRAS G12C-positive Tumours September 5, 2023 Load more HOT NEWS For Women Returning from Breast Cancer Treatment, Work Often Changes Involuntarily Some Children with Wilms Tumor Can Receive Less Therapy, Study Suggests Data from a Large Cohort of Patients with mRCC Demonstrate the... News digest – light-activated nanoparticles, Government’s obesity plans, tumour ‘glue’ and...
